Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients - PubMed (original) (raw)
Affiliations
- PMID: 23898484
Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients
Subramanian Kumar et al. Indian J Biochem Biophys. 2013 Jun.
Abstract
Breast cancer is the second most common malignant disease affecting Indian women and is the leading cause of cancer-related mortality. MicroRNAs (miRNAs) are remarkably stable in blood, which makes them novel and promising biomarkers for cancer detection and diagnosis. In this study, we investigated whether expression levels of circulating specific miRNAs, such as microRNA-21 (miR-21) and microRNA-146a (miR-146a) could be used as potential biomarkers in plasma of breast cancer patients and healthy individuals. We compared the expression levels of breast cancer associated specific miRNA--miR-21 and miR-146a in plasma samples of histopathologically reported 14 patients (aged 35-61 yrs) with breast cancer and an additional 8 healthy volunteers (aged 35-54 yrs). The miRNA expression level was determined by TaqMan quantitative PCR (qPCR) assay. The miRNA expression level of each sample was normalized to that of miR-16 as reference and expressed as relative expression (2(deltaCt)). Our results showed that the circulating level of miR-21 and miR-146a were significantly higher in plasma samples of breast cancer patients, when compared to those of healthy controls (p < 0.0004 and p < 0.005, respectively). Thus, analyzing expression of miR-21 and miR-146a from plasma samples of breast cancer patients might be useful in the diagnosis of breast cancer. However, further studies with larger number of patients and control individuals are needed to confirm the results.
Similar articles
- Decreased serum miR-181a is a potential new tool for breast cancer screening.
Guo LJ, Zhang QY. Guo LJ, et al. Int J Mol Med. 2012 Sep;30(3):680-6. doi: 10.3892/ijmm.2012.1021. Epub 2012 Jun 11. Int J Mol Med. 2012. PMID: 22692639 - Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls.
Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao Y, Tang J, Chen X, Dai J, Wei Q, Zhang C, Shen H. Hu Z, et al. Carcinogenesis. 2012 Apr;33(4):828-34. doi: 10.1093/carcin/bgs030. Epub 2012 Feb 1. Carcinogenesis. 2012. PMID: 22298638 - Analysis of serum genome-wide microRNAs for breast cancer detection.
Wu Q, Wang C, Lu Z, Guo L, Ge Q. Wu Q, et al. Clin Chim Acta. 2012 Jul 11;413(13-14):1058-65. doi: 10.1016/j.cca.2012.02.016. Epub 2012 Feb 23. Clin Chim Acta. 2012. PMID: 22387599 - Circulating miRNAs as new blood-based biomarkers for solid cancers.
Redova M, Sana J, Slaby O. Redova M, et al. Future Oncol. 2013 Mar;9(3):387-402. doi: 10.2217/fon.12.192. Future Oncol. 2013. PMID: 23469974 Review. - Technology in MicroRNA Profiling: Circulating MicroRNAs as Noninvasive Cancer Biomarkers in Breast Cancer.
Pimentel F, Bonilla P, Ravishankar YG, Contag A, Gopal N, LaCour S, Lee T, Niemz A. Pimentel F, et al. J Lab Autom. 2015 Oct;20(5):574-88. doi: 10.1177/2211068214561788. Epub 2014 Dec 18. J Lab Autom. 2015. PMID: 25524488 Review.
Cited by
- Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer.
Wang RJ, Zheng YH, Wang P, Zhang JZ. Wang RJ, et al. Int J Clin Exp Pathol. 2015 Jan 1;8(1):765-71. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 25755772 Free PMC article. - Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.
Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Senti C, Brambilla P, Milani M, Spada D, Pedrazzoli P, Martino M, Bottini A, Generali D; Solid Tumor Working Party of European Blood and Marrow Transplantation Society (EBMT). Ravelli A, et al. Tumour Biol. 2015 Sep;36(9):6653-65. doi: 10.1007/s13277-015-3944-7. Epub 2015 Aug 26. Tumour Biol. 2015. PMID: 26307395 Review. - Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
Stückrath I, Rack B, Janni W, Jäger B, Pantel K, Schwarzenbach H. Stückrath I, et al. Oncotarget. 2015 May 30;6(15):13387-401. doi: 10.18632/oncotarget.3874. Oncotarget. 2015. PMID: 26033453 Free PMC article. Clinical Trial. - Metformin Caused Radiosensitivity of Breast Cancer Cells through the Expression Modulation of miR-21-5p/SESN1axis.
Saffari F, Momeni A, Ramezani M, Ansari Y, Moghbelinejad S. Saffari F, et al. Asian Pac J Cancer Prev. 2023 Nov 1;24(11):3715-3727. doi: 10.31557/APJCP.2023.24.11.3715. Asian Pac J Cancer Prev. 2023. PMID: 38019229 Free PMC article. - miR-1225-5p inhibits non-small cell lung cancer cell proliferation, migration and invasion, and may be a prognostic biomarker.
Li B, Zhang F, Li H. Li B, et al. Exp Ther Med. 2020 Dec;20(6):172. doi: 10.3892/etm.2020.9302. Epub 2020 Oct 9. Exp Ther Med. 2020. PMID: 33101465 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical